These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34531718)

  • 1. The Gut Microbiome and Substance Use Disorder.
    Russell JT; Zhou Y; Weinstock GM; Bubier JA
    Front Neurosci; 2021; 15():725500. PubMed ID: 34531718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs and Bugs: The Gut-Brain Axis and Substance Use Disorders.
    Simpson S; Mclellan R; Wellmeyer E; Matalon F; George O
    J Neuroimmune Pharmacol; 2022 Jun; 17(1-2):33-61. PubMed ID: 34694571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.
    Angoa-Pérez M; Kuhn DM
    Pharmacol Rev; 2021 Apr; 73(2):571-596. PubMed ID: 33597276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of neuroimaging and gut-brain axis research for substance use disorders.
    Colon-Perez L; Montesinos J; Monsivais M
    Brain Res; 2022 Apr; 1781():147835. PubMed ID: 35172178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Microbiome-Gut-Brain Axis, a Potential Therapeutic Target for Substance-Related Disorders.
    Fu X; Chen T; Cai J; Liu B; Zeng Y; Zhang X
    Front Microbiol; 2021; 12():738401. PubMed ID: 34690981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of addiction treatment among U.S. adults with history of incarceration and substance use disorders.
    Tsai J; Gu X
    Addict Sci Clin Pract; 2019 Mar; 14(1):9. PubMed ID: 30836991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential role for the gut microbiome in substance use disorders.
    Meckel KR; Kiraly DD
    Psychopharmacology (Berl); 2019 May; 236(5):1513-1530. PubMed ID: 30982128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of substance use disorders on clinical outcomes in older-adult psychiatric inpatients.
    Lane SD; da Costa SC; Teixeira AL; Reynolds CF; Diniz BS
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):e323-e329. PubMed ID: 29044798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
    Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
    Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance-Induced Psychiatric Disorders, Epigenetic and Microbiome Alterations, and Potential for Therapeutic Interventions.
    Nohesara S; Mostafavi Abdolmaleky H; Thiagalingam S
    Brain Sci; 2024 Jul; 14(8):. PubMed ID: 39199463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbial glutamate metabolism predicts intravenous cocaine self-administration in diversity outbred mice.
    Binh Tran TD; Nguyen H; Sodergren E; Addiction CFSNO; Dickson PE; Wright SN; Philip VM; Weinstock GM; Chesler EJ; Zhou Y; Bubier JA
    Neuropharmacology; 2023 Mar; 226():109409. PubMed ID: 36592885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How life events may confer vulnerability to addiction: the role of epigenetics.
    Liu SX; Harris AC; Gewirtz JC
    Front Mol Neurosci; 2024; 17():1462769. PubMed ID: 39359689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One Is Not Enough: Understanding and Modeling Polysubstance Use.
    Crummy EA; O'Neal TJ; Baskin BM; Ferguson SM
    Front Neurosci; 2020; 14():569. PubMed ID: 32612502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linking the gut microbiome to microglial activation in opioid use disorder.
    Antoine D; Venigalla G; Truitt B; Roy S
    Front Neurosci; 2022; 16():1050661. PubMed ID: 36590299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic epidemiology of substance use disorder: A review.
    Prom-Wormley EC; Ebejer J; Dick DM; Bowers MS
    Drug Alcohol Depend; 2017 Nov; 180():241-259. PubMed ID: 28938182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human brain organoids for understanding substance use disorders.
    Li K; Gu L; Cai H; Lu HC; Mackie K; Guo F
    Drug Metab Pharmacokinet; 2024 Jul; 58():101031. PubMed ID: 39146603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiome and substances of abuse.
    Salavrakos M; Leclercq S; De Timary P; Dom G
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110113. PubMed ID: 32971216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults.
    Young JT; Carruthers S; Kaye S; Allsop S; Gilsenan J; Degenhardt L; van de Glind G; van den Brink W; Preen D
    Drug Alcohol Rev; 2015 Nov; 34(6):683-93. PubMed ID: 25790353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personality disorders and the 3-year course of alcohol, drug, and nicotine use disorders.
    Hasin D; Fenton MC; Skodol A; Krueger R; Keyes K; Geier T; Greenstein E; Blanco C; Grant B
    Arch Gen Psychiatry; 2011 Nov; 68(11):1158-67. PubMed ID: 22065531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.